An antineoplastic agent
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Hydroxyurea

Item No. 23725

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-hydroxy-urea
CAS Number
127-07-1
Synonyms
  • NCI C04831
  • NSC 32065
Molecular Formula
CH4N2O2
Formula Weight
76.1
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 1 mg/mlDMSO: 1 mg/mlWater: 10 mg/ml
SMILES
NC(NO)=O
InChi Code
InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
InChi Key
VSNHCAURESNICA-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 g

    $75

    Add

    10 g

    $134

    Add

    25 g

    $259

    Add

    50 g

    $479

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Hydroxyurea is an antineoplastic agent that inhibits DNA replication and cell proliferation and induces cell cycle arrest in the G1/S phase.1 It inhibits proliferation of NCI H460 human lung cancer cells in vitro (IC50 = 0.56 mM).2 Hydroxyurea reduces ribonucleoside diphosphate reductase (RNR) activity by 75% when used at a concentration of 5 mM via degradation of its active site tyrosyl radical.1,3 In a humanized mouse model of sickle cell disease (SCD), it reduces leukocyte adhesion and extravasation via NO production and a cGMP-dependent pathway.4 Hydroxyurea also inhibits HIV-1 viral replication in peripheral blood mononuclear cells (PBMCs) in a dose-dependent manner with an IC90 value of 0.4 mM.5,6 Formulations containing hydroxyurea have been used to treat cancer, SCD, and psoriasis.1,7,8

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Madaan, K., Kaushik, D., and Verma, T. Hydroxyurea: A key player in cancer chemotherapy. Expert Rev. Anticancer Ther. 12(1), 19-29 (2012).

    2. Yakisich, J.S., Azad, N., Venkatadri, R., et al. Digitoxin and its synthetic analog MonoD have potent antiproliferative effects on lung cancer cells and potentiate the effects of hydroxyurea and paclitaxel. Oncol. Rep. 35(2), 878-886 (2016).

    3. Krakoff, I.H., Brown, N.C., and Reichard, P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res. 28(8), 1559-1565 (1968).

    4. Almeida, C.B., Scheiermann, C., Jang, J.E., et al. Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Blood 120(14), 2879-2888 (2012).

    5. Gao, W.-Y., Johns, D.G., and Mitsuya, H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides. Mol. Pharmacol. 46(4), 767-772 (1994).

    6. Lori, F., and Lisziewicz, J. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin. Infect. Dis. 30(Suppl 2), S193-S197 (2000).

    7. Platt, O.S. Hydroxyurea for the treatment of sickle cell anemia. N. Engl. J. Med. 358(13), 1362-1369 (2008).

    8. Boyd, A.S., and Neldner, K.H. Hydroxyurea therapy. J. Am. Acad. Dermatol. 25(3), 518-524 (1991).